CryoPort (NASDAQ:CYRX) Hits New 12-Month High – Should You Buy?

CryoPort, Inc. (NASDAQ:CYRX)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $13.79 and last traded at $13.8010, with a volume of 113845 shares changing hands. The stock had previously closed at $13.03.

Analysts Set New Price Targets

CYRX has been the subject of a number of analyst reports. Guggenheim boosted their price objective on CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Craig Hallum initiated coverage on CryoPort in a research report on Monday, March 30th. They set a “buy” rating and a $15.00 price objective for the company. KeyCorp boosted their price objective on CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Wednesday. Weiss Ratings upgraded CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 6th. Finally, BTIG Research boosted their price objective on CryoPort from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.69.

CryoPort Trading Up 1.1%

The stock has a 50-day simple moving average of $10.19 and a 200-day simple moving average of $9.62. The company has a market cap of $716.69 million, a price-to-earnings ratio of 10.53 and a beta of 1.75.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The business had revenue of $47.80 million for the quarter, compared to analyst estimates of $44.86 million. As a group, research analysts expect that CryoPort, Inc. will post -0.74 EPS for the current fiscal year.

Insiders Place Their Bets

In other CryoPort news, CFO Robert Stefanovich sold 38,700 shares of the business’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $7.76, for a total transaction of $300,312.00. Following the completion of the transaction, the chief financial officer owned 255,701 shares in the company, valued at approximately $1,984,239.76. The trade was a 13.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jerrell Shelton sold 7,918 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $63,344.00. Following the transaction, the chief executive officer owned 1,054,501 shares of the company’s stock, valued at $8,436,008. This trade represents a 0.75% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 59,939 shares of company stock worth $471,183. 10.00% of the stock is owned by company insiders.

Institutional Trading of CryoPort

A number of hedge funds and other institutional investors have recently modified their holdings of CYRX. AQR Capital Management LLC raised its stake in shares of CryoPort by 285.5% in the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after buying an additional 194,482 shares in the last quarter. Creative Planning bought a new stake in shares of CryoPort in the 2nd quarter worth $96,000. Rhumbline Advisers raised its stake in shares of CryoPort by 17.6% in the 2nd quarter. Rhumbline Advisers now owns 92,098 shares of the company’s stock worth $687,000 after buying an additional 13,778 shares in the last quarter. American Century Companies Inc. raised its stake in shares of CryoPort by 24.4% in the 2nd quarter. American Century Companies Inc. now owns 88,876 shares of the company’s stock worth $663,000 after buying an additional 17,459 shares in the last quarter. Finally, Prudential Financial Inc. bought a new stake in shares of CryoPort in the 2nd quarter worth $254,000. Institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.